- 7 days after the seconds dose, 90% efficacy was reported 
- 28 days after the initial dose, protection is achieved
- No reports of severe adverse events 

Smith College

Pfizer BNT162b1 First Interim from Phase 3 Study

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study | Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against. Accessed 20 Nov. 2020.

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in FIrst Interim Analysis form Phase 3 Study

- The DMC performed its first analysis on all cases, split between vaccinated individuals and those who received the placebo.
 indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. 
- 2-dose schedule 

Methods of Pfizer BNT162b1 First Interim from Phase 3 Study

Results of Pfizer BNT162b1 First Interim from Phase 3 Study

At 90% efficacy with no serious adverse effects, this vaccine shows promise to effective for widespread protection. At the time of writing, Pfizer and BioNTech continue to enroll participants and acruse safety data

Learn Before

Related